Darlene Deptula-Hicks

Darlene Deptula-Hicks Email and Phone Number

Interim Chief Financial Officer @ Normunity
Boston, MA, US
Darlene Deptula-Hicks's Location
Greater Boston, United States, United States
Darlene Deptula-Hicks's Contact Details
About Darlene Deptula-Hicks

A strategic and entrepreneurial business leader with extensive biotech, pharmaceutical, therapeutics, medical device, AI and diagnostics industry experience. Demonstrated ability to build, motivate, and manage cross-functional teams and build strong external partnerships to achieve business results and increase shareholder value. Extensive buy and sell side investor relations experience with longstanding track record of raising capital in both public and private equity markets and IPO experience. In addition to leadership and responsibility as CFO for finance, accounting, SEC reporting, Nasdaq and SOX compliance, M&A, investor relations, IT, treasury, tax, legal and HR activities also strong operational and commercial experience with in-depth understanding of product commercialization, supply chain, manufacturing and quality, product development, clinical and regulatory, BD and licensing. Board member and Audit Committee Chair since 2006. Public & Private Company Expertise: Pre-IPO/IPO/post-IPO deal experience with deep industry knowledge across life sciences with strong capital markets experience. Expertise in both public and private companies, from VC start-ups to mid-size companies and expertise with all GAAP, SEC reporting, Nasdaq, IFRS and SOX compliance and knowledge of complex revenue recognition. Capital Raising & Investor Relations: Longstanding track record of raising capital in public and private equity markets including IPO’s, secondary/follow-on public offerings, private equity, debt and venture financings of over $350M. Strong investment banker, analyst and investor contacts, and investor presentation skills. Serve as a key interface to the capital markets. Growth Strategies & M&A: Strong background in M&A transactions and roll-up strategies including, identify acquisition targets and leading M&A negotiations to completion and integration, licensing agreements and collaborations, and sell side transactions.

Darlene Deptula-Hicks's Current Company Details
Normunity

Normunity

View
Interim Chief Financial Officer
Boston, MA, US
Website:
normunity.com
Employees:
24
Darlene Deptula-Hicks Work Experience Details
  • Normunity
    Interim Chief Financial Officer
    Normunity
    Boston, Ma, Us
    View
  • Greywolf Therapeutics
    Chief Financial Officer
    Greywolf Therapeutics Jul 2024 - Present
    Milton, Oxfordshire, Gb
    View
  • Avacta
    Board Member
    Avacta Jun 2024 - Present
    Wetherby, England, Gb
    (AIM:AVCT)
    View
  • Aerami Therapeutics
    Board Member And Audit Committee Chair
    Aerami Therapeutics Oct 2021 - Present
  • Abcuro, Inc
    Board Member & Audit Committee Chair
    Abcuro, Inc Jul 2021 - Present
    Abcuro is a clinical stage biotechnology company developing treatments for autoimmune and cancer indications modulated by cytotoxic T and NK cells that express the inhibitory immune checkpoint receptor KLRG1.
    View
  • Crimson Consulting, Llc
    Chief Financial Officer/Business Owner
    Crimson Consulting, Llc Jan 2018 - Present
    Greywolf Therapeutics - Chief Financial Officer - current Normunity Inc. - Acting Chief Financial Officer - currentAerami Therapeutics - Board Member, Audit Committee ChairF-Star Therapeutics, Inc., (NASDAQ:FSTX) Chief Financial Officer Northern Biologics, Inc. - Chief Financial Officer CannaKorp, Inc. - Chief Financial OfficerProviding strategic and operational financial consulting services to life science and technology companies on an Acting or Fractional CFO consulting basis (part-time, interim or project basis). Services range from execution of day-to-day accounting and finance functions to strategic CFO advisory services, public and venture capital raising, financial planning and analysis, SEC reporting, M&A transactions and Initial Public Offerings enabling companies at all stages to grow and optimize the value of their business.
  • F-Star Therapeutics, Inc.
    Chief Financial Officer
    F-Star Therapeutics, Inc. May 2019 - Mar 2023
    Cambridge, Cambridgeshire, Gb
    NASDAQ:FSTX
    View
  • Giner Life Sciences
    Member Board Of Directors
    Giner Life Sciences Apr 2019 - Sep 2021
    Newton, Ma, Us
    Giner Life Sciences applies its world class technologies in electrochemical oxygenation to medical and life science applications with a focus on its miniature oxygen generation devices for implantable and wearable applications.
    View
  • T2 Biosystems
    Svp And Chief Financial Officer
    T2 Biosystems May 2017 - Jan 2018
    Lexington, Ma, Us
    T2 Biosystems (NASDAQ:TTOO) is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis, one of the most deadly and expensive conditions in hospitals today, and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics.
    View
  • Xenetic Biosciences, Inc.
    Board Member And Audit Committee Chair
    Xenetic Biosciences, Inc. Apr 2014 - Aug 2017
    Framingham, Ma, Us
    Xenetic Biosciences (NASDAQ:XBIO) is a biopharmaceutical company developing next generation biologic drugs and novel oncology therapeutics.
    View
  • Pieris Pharmaceuticals
    Sr. Vice President & Chief Financal Officer
    Pieris Pharmaceuticals Dec 2014 - Feb 2017
    Boston, Massachusetts, Us
    Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) is a clinical-stage biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that have the potential to be safer and more effective than conventional approaches. Anticalins show promise in addressing high-unmet medical needs and expanding the potential of targeted therapeutics. The company currently has a diverse proprietary pipeline and has ongoing R&D collaborations with Daiichi Sankyo, the Sanofi Group, Zydus Cadila, Stelis Biopharma and Allergan.
    View
  • Several Companies
    Acting Cfo & Consultant
    Several Companies Nov 2014 - Sep 2015
    Providing strategic and operational consulting to biotech and medical device companies on an acting/interim CFO or consulting basis. Current engagements include:Pieris Pharmaceutical Corp. (OTC:PIRS) – Acting CFO for this clinical-stage biotechnology company through a reverse merger into a public shell with a pipe financing, and its subsequent operations as a public company. Pieris is advancing its proprietary AntiCalin technology with a diverse proprietary pipeline and multiple ongoing R&D collaborations. Engagement through Danforth Associates.Claritas Genomics – Acting CFO for this venture-backed spin-out of Boston Children’s Hospital. Claritas is a clinical genetic testing company that combines the clinical expertise of the world’s best pediatric specialists with the next generation sequencing technology to inform and improve patient care. Engagement through Danforth Associates.Ivenix – Providing CFO consulting services for this venture-backed medical device company with a vision to transform the hospital infusion pump market through its breakthrough infusion management system in late stage development and early commercialization.
  • Microline Surgical, Inc.
    Vp And Chief Financial Officer
    Microline Surgical, Inc. Jun 2012 - Nov 2014
    Amersfoort, Utrecht, Nl
    Microline Surgical, Inc. with offices in Boston, Amsterdam, Paris, Tokyo and Hong Kong is the leader in reposable surgical instruments offering a broad range of open and minimally invasive devices that offer high quality precision, combined with ease of use and cost effectiveness.
    View
  • Usfalcon
    Board Member & Audit Committee Chair
    Usfalcon 2007 - 2014
    Cary, Nc, Us
    USF provides integrated technical solutions world wide to US government clients in national defense, security and intelligence.
    View
  • Icad, Inc.
    Executive Vice President And Chief Financial Officer
    Icad, Inc. 2006 - 2011
    Nashua, New Hampshire, Us
    iCAD, Inc. (Nasdaq: ICAD) - An industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer.
    View
  • Oni Medical Systems, Inc.
    Executive Vice President And Chief Financial Officer
    Oni Medical Systems, Inc. 2002 - 2006
    Us
    A mid stage, venture capital backed, designer and manufacturer of dedicated purpose, high field, diagnostic imaging systems for orthopedic and other applications.
    View
  • Implant Science Corporation
    Vice President And Chief Financial Officer
    Implant Science Corporation 1998 - 2001
    A publicly traded (AMEX:IMX) designer and manufacturer of radiation oncology, interventional cardiology and orthopedic devices.

Darlene Deptula-Hicks Skills

Revenue Recognition Mergers Medical Devices Venture Capital Ipo Sec Filings Strategy Risk Management Biotechnology Investor Relations Divestitures Mergers And Acquisitions Private Equity Leadership Healthcare Software Corporate Governance Start Ups Cross Functional Team Leadership Expense Management Business Strategy Due Diligence Sarbanes Oxley Act Negotiation Forecasting Corporate Development Managerial Finance Executive Management Restructuring Business Planning Financial Analysis Internal Controls Corporate Finance Accounting Cost Accounting Analysis Auditing Gaap M&a Experience Acquisition Integration Financial Modeling Sarbanes Oxley Cash Flow Financial Reporting Finance Working Capital Management Public Companies Business Valuation Strategic Financial Planning Us Gaap

Darlene Deptula-Hicks Education Details

  • The Tuck School Of Business At Dartmouth
    The Tuck School Of Business At Dartmouth
    Executive Education Program
  • Rivier University
    Rivier University
    Business
  • Southern New Hampshire University
    Southern New Hampshire University
    Accounting

Frequently Asked Questions about Darlene Deptula-Hicks

What company does Darlene Deptula-Hicks work for?

Darlene Deptula-Hicks works for Normunity

What is Darlene Deptula-Hicks's role at the current company?

Darlene Deptula-Hicks's current role is Interim Chief Financial Officer.

What is Darlene Deptula-Hicks's email address?

Darlene Deptula-Hicks's email address is da****@****tar.com

What is Darlene Deptula-Hicks's direct phone number?

Darlene Deptula-Hicks's direct phone number is +178145*****

What schools did Darlene Deptula-Hicks attend?

Darlene Deptula-Hicks attended The Tuck School Of Business At Dartmouth, Rivier University, Southern New Hampshire University.

What skills is Darlene Deptula-Hicks known for?

Darlene Deptula-Hicks has skills like Revenue Recognition, Mergers, Medical Devices, Venture Capital, Ipo, Sec Filings, Strategy, Risk Management, Biotechnology, Investor Relations, Divestitures, Mergers And Acquisitions.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.